Ariel Weinberger, Ph.D.
Dr. Ariel Weinberger is CEO and co-Founder of Autonomous. He has led the company since its founding and has raised significant non-dilutive funding to transition its core therapeutic candidates into animals. Prior to founding Autonomous, Ariel was a Principal Investigator and Wyss Fellow at Harvard Medical School. Ariel received his Ph.D. in Biophysics from the University of California, Berkeley and is an expert on microbial evolution and drug resistance. He is responsible for translating the Therapeutic Interfering Particle (TIP) concept from HIV to novel viruses and cancers, and has been a leading author in prestigious scientific journals, including: Cell, Trends in Biotechnology, PLoS Computational Biology, Cell Host and Microbe, & mBio.
Leor Weinberger, Ph.D.
Dr. Leor Weinberger is the co-founder of Autonomous and Chair of its Scientific Advisory Board (SAB). He is the William and Ute Bowes Distinguished Professor at the Gladstone Institutes, Professor of both Pharmaceutical Chemistry as well as Biochemistry & Biophysics at the University of California, San Francisco (UCSF), and the Founding Director of the Gladstone Center for Cell Circuitry. Leor is a leading expert on HIV and herpes virology, a noted synthetic biologist and the leading author of seminal publications in: Cell, Science, Nature Genetics and the Proceedings of National Academies of Sciences (PNAS). He is also a Pew Fellow, a Sloan Foundation Fellow, a winner of the Bill & Melinda Gates Foundation Challenge Prize, and awardee of the NIH Director's: Pioneer, New Innovator Awards and Avante-Garde Awards. He is the inventor of the TIP evolving therapy concept, and the co-inventor of the Deletion Platform that engineers TIP therapeutics in just weeks.
Timothy Notton, Ph.D.
Dr. Timothy Notton is Director of Engineering at Autonomous and co-inventor of the TIP concept and the TIP Deletion Platform. He earned his Ph.D. in Bioengineering from both the University of California, San Francisco and the University of California, Berkeley, where he engineered the first TIP prototypes to control HIV and Zika. Tim is the inventor of the Deletion Platform to rapidly engineer TIPs against any virus or cancer. He is also the inventor of the Robotic Bioreactor platform being developed at Autonomous to indefinitely test therapeutic safety and efficacy. For his work, Tim was recently awarded the DARPA Risers prize, which is given to 50 of the leading up-and-coming scientists identified by DARPA.
Paul Leon, ph.D.
Dr. Paul Leon is Associate Director of Business Development and Senior Scientist at Autonomous. Prior to joining Autonomous, Paul quarterbacked pharmaceutical product launches and advised private biotechnology companies as a Senior Consultant at Navigant Consulting, Inc. He earned his Ph.D. in Biomedical Sciences at the Mount Sinai School of Medicine, where he studied virus-immune interactions and helped develop novel universal flu vaccine approaches for influenza. Paul has published in leading peer-reviewed journals, including: Proceedings of the National Academy of Sciences (PNAS), Immunity, the Journal of Clinical Investigations, Nature Communications, Cell Host & Microbe, & PLoS Pathogens.